Divi’s Laboratories Ltd. (DIVISLAB) Share Price Hits New 52-Week High
- July 29, 2026
- Posted by: Harsh Piplani
- Category: News
Divi’s Laboratories Ltd. Share Price has reached a fresh 52-week high, closing at Rs 7,565.25, marking a 1.95% increase from the previous close of Rs 7,420.45. The stock opened at Rs 7,437.3 and reached a high of Rs 7,585.5 during the day. The company’s market capitalisation now stands at Rs 1,96,880.79 crore. This surge in price highlights the stock’s strong performance in the market, capturing investor attention.
Divi’s Laboratories Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 7,565.25 |
| Previous Close | Rs 7,420.45 |
| Today's Change | +Rs 144.8 (+1.95%) |
| Day Open | Rs 7,437.3 |
| Fresh 52-Week High | Rs 7,585.5 |
| Day Low | Rs 7,437.3 |
| Current Volume | 4,274 |
| Turnover | Rs 3.23 crore |
| Market Capitalisation | Rs 1,96,880.79 crore |
Today, Divi’s Laboratories Ltd. Share Price opened at Rs 7,437.3 and climbed to a high of Rs 7,585.5, setting a new 52-week high. The stock closed at Rs 7,565.25, up by Rs 144.8 or 1.95% from the previous close. The day’s low was also the opening price, indicating a strong upward movement throughout the trading session. The turnover for the day was Rs 3.23 crore with a volume of 4,274 shares, reflecting moderate trading activity.
Divi's Laboratories Ltd. (DIVISLAB) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,96,880.79 crore |
| P/E Ratio | 29.31x |
| P/B Ratio | 0.43x |
| ROE | -2.89% |
| ROCE | -0.26% |
Divi's Laboratories Ltd. was valued at a P/E ratio of 29.31x, a P/B ratio of 0.43x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Company P/E Ratio | 29.31x |
| Benchmark Median P/E | 21.06x |
| Benchmark Average P/E | 68.59x |
| Benchmark P/E Range | 0x to 3,439.3x |
| Company P/B Ratio | 0.43x |
| Benchmark Median P/B | 1.88x |
| Company ROE | -2.89% |
| Benchmark Median ROE | 10.91% |
| Company ROCE | -0.26% |
| Benchmark Median ROCE | 13.2% |
| Company Market Capitalisation | Rs 1,96,880.79 crore |
| Benchmark Median Market Cap | Rs 140.64 crore |
Divi's Laboratories Ltd. (DIVISLAB) is classified under sector: Healthcare. The numerical benchmark uses 198 same sector companies from the supplied master-data set.
Divi's Laboratories Ltd. (DIVISLAB) has a P/E ratio of 29.31x, which is above the benchmark median of 21.06x, a difference of +39.17%. The benchmark contains 198 companies with P/E data, ranging from 0x to 3,439.3x. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Divi's Laboratories Ltd. (DIVISLAB) has a ROE of -2.89%, which is below the benchmark median of 10.91%, a difference of -126.49%. Divi's Laboratories Ltd. (DIVISLAB) has a ROCE of -0.26%, which is below the benchmark median of 13.2%, a difference of -101.97%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,921.65 | 29.31 | 0.43 | -2.89 | -0.26 |
| Kwality Pharmaceuticals Ltd. | KPL | 2,815.27 | 39.89 | 8.12 | 28.21 | 26.35 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,476.69 | 169.37 | 3.13 | 13.9 | 12.97 |
| Beta Drugs Ltd. | BETA | 2,472.93 | 56.38 | 8.92 | 18.65 | 22.17 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,444.35 | 34.87 | 7.06 | -2.6 | 16.92 |
Divi's Laboratories Ltd. (DIVISLAB) has a P/E ratio of 29.31x compared with the displayed peer median of 39.89x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Divi's Laboratories Ltd. (DIVISLAB) has a market capitalisation of Rs 1,96,880.79 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching Divi’s Laboratories Ltd.
- Divi’s Laboratories Ltd. Share Price reached a new 52-week high, indicating strong market interest.
- The stock’s P/E ratio is above the sector median, suggesting a relatively higher valuation.
- Despite negative ROE and ROCE, the company maintains a large market cap.
- The Healthcare sector’s wide valuation range provides context for the stock’s performance.
About Divi’s Laboratories Ltd.
Divi’s Laboratories Ltd. is a prominent player in the Healthcare sector, focusing on the production of active pharmaceutical ingredients (APIs) and intermediates. The company serves a global clientele, providing high-quality products for various therapeutic areas. With a strong emphasis on research and development, Divi’s Laboratories Ltd. continues to innovate and expand its product portfolio, maintaining a competitive edge in the industry.
Track Divi’s Laboratories Ltd. Share Price on Univest
Use Divi's Laboratories Ltd. (DIVISLAB) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors can track Divi’s Laboratories Ltd. Share Price, technical indicators, fundamental ratios, shareholding pattern, 52-week levels, and market insights on Univest. Stay informed about the latest developments and market trends.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the current share price of Divi's Laboratories Ltd.?
Ans. The current share price of Divi's Laboratories Ltd. is Rs 7,565.25, marking a fresh 52-week high. The stock has shown a 1.95% increase from the previous close. The stock moved 1.95% during the session.
What is the market capitalisation of Divi's Laboratories Ltd.?
Ans. The market capitalisation of Divi's Laboratories Ltd. is Rs 1,96,880.79 crore, reflecting its significant size within the Healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 29.31x.
What is the P/E ratio of Divi's Laboratories Ltd.?
Ans. Divi's Laboratories Ltd. has a P/E ratio of 29.31, which is above the sector median of 21.06, indicating a higher valuation relative to many peers. The company trades at a P/E ratio of 29.31x.
How does Divi's Laboratories Ltd. compare to its peers?
Ans. Divi's Laboratories Ltd. has a larger market cap compared to peers like Dishman Carbogen Amcis Ltd. and Kwality Pharmaceuticals Ltd., but it has negative ROE and ROCE. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Sai Parenteral's.
What sector does Divi's Laboratories Ltd. operate in?
Ans. Divi's Laboratories Ltd. operates in the Healthcare sector, focusing on the production of active pharmaceutical ingredients and intermediates. The stock belongs to the Healthcare sector. 198 comparable companies were included in the benchmark.
What are the ROE and ROCE of Divi's Laboratories Ltd.?
Ans. Divi's Laboratories Ltd. has a negative ROE of -2.89% and ROCE of -0.26%, indicating challenges in profitability and capital efficiency. ROE stands at -2.89%. ROCE stands at -0.26%. The relevant peer median ROE is 10.91%.
What is the P/B ratio of Divi's Laboratories Ltd.?
Ans. The P/B ratio of Divi's Laboratories Ltd. is 0.43, significantly lower than the sector median of 1.88, suggesting potential undervaluation. The company trades at a P/E ratio of 29.31x. Its P/B ratio is 0.43x.
What is the sector median P/E ratio?
Ans. The sector median P/E ratio for the Healthcare sector is 21.06, providing a benchmark for evaluating Divi's Laboratories Ltd.'s valuation. The company trades at a P/E ratio of 29.31x. Its P/B ratio is 0.43x.
